Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Synthorx Inc (THOR) USD0.001

Sell:$13.56 Buy:$15.02 Change: $0.02 (0.14%)
NASDAQ:0.19%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$13.56
Buy:$15.02
Change: $0.02 (0.14%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$13.56
Buy:$15.02
Change: $0.02 (0.14%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Synthorx, Inc. is a biopharmaceutical company. The Company is focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders. Its platform technology expands the genetic code by adding a new deoxyribonucleic acid (DNA) base pair and is designed to create optimized biologics, which is referred as Synthorins. The Company’s lead product candidate, THOR-707, is a variant of IL-2 designed to kill tumor cells by increasing CD8+ T and natural killer (NK), cells without causing vascular leak syndrome (VLS), observed with IL-2 (aldesleukin). Its cytokine Synthorin programs, including IL-2, IL-10 and IL-15 for the treatment of cancer, and another IL-2 Synthorin program for the treatment of autoimmune disorders.

Contact details

Address:
11099 N Torrey Pines Rd Ste 190
LA JOLLA
92037-1029
United States
Telephone:
+1 (858) 7504700
Website:
https://synthorx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
THOR
ISIN:
US87167A1034
Market cap:
$407.52 million
Shares in issue:
32.27 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Pratik Shah
    Independent Chairman of the Board
  • Laura Shawver
    President, Chief Executive Officer, Director
  • Tighe Reardon
    Acting Chief Financial Officer
  • Marcos Milla
    Chief Scientific Officer
  • Joseph Leveque
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.